I do like looking for income stock in the Small/Mid asset class, though they can be hard to find. Generally, I can find between 6 to 7, but these days, the shelves tend to be bare. Here is the process:
- Domestic Small or Mid Caps
- Good daily liquidity
- Financially Strong
- Yield > 2%
- Persistent dividend growth
- Beta < 1
- Positive Free Cash Flow
- Payout Ratio < 50
- Present Value based on Discounted Dividend Model < Current Price
This screen is a solid performer, and has averaged a 12.67% annual yield since 2002. This compares favorably to the Russell 2000 at 8.37%.
As I said, there is only one passing candidate, and here it is:
NewMarket Corp (NYSE: $NEU)-- NewMarket Corporation, through its subsidiaries, engages in the petroleum additives businesses. The company offers lubricant additives for use in various vehicle and industrial applications, including engine oils, transmission fluids, off-road powertrain and hydraulic systems, gear oils, hydraulic oils, turbine oils, and other applications where metal-to-metal moving parts are utilized; and engine oil, driveline, and industrial additives. It also provides fuel additives that are used to enhance the oil refining process and the performance of gasoline, diesel, biofuels, and other fuels to industry, government, original equipment manufacturers, and individual customers. In addition, it engages in the antiknock compounds business, as well as contracted manufacturing and services activities. The company has operations in the North America, Latin America, Asia Pacific, Europe, the Middle East, Africa, and India. NewMarket Corporation was founded in 1887 and is headquartered in Richmond, Virginia.
It has a current yield of 2.37%, and the recent price drop has presented a potential buying opportunity. Of course, do your own research.
Disclosures:
In no way am I saying to buy this now. Do your own due diligence. The fact that only one stock is available is a flag about the overall market, so proceed with caution.
We looked through our database of over 550+ smid cap biotech companies & their drugs/catalysts and identified those with new clinical data coming at ASCO.
Tried to get all the info into this post but some things are difficult so you can find the full post with tables, etc here
--------------------- Article -------------------
*Info last updated 5/27/21
(Click here for our previous (5/20/21) ASCO21 blog article.)
The annual meeting of the American Society of Clinical Oncology (ASCO21) is being held this year from June 4-8, 2021. With over 40,000 registrants, the ASCO® annual meeting is one of the largest biopharmaceutical conferences of the year (https://conferences.asco.org/am/meeting-demographics). Usually, it is held at Chicago's McCormick Place. This year, like last year, it is being held virtually due to the pandemic. The key dates for this year's conference are shown in FIG. 1. In this virtual event, all of the posters will be released on June 8, 2021 at 9AM EST. Thus, we believe many of those posters will be publicly available to investors, even those who have not registered for ASCO21, on company web sites shortly thereafter.
FIG. 1 ASCO21 Key dates (https://www.asco.org/about-asco/press-center/pr-professionals)
Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. As experienced biopharma investors understand, the value of a biopharma company is based in large part on the value of its clinical assets. This value takes into account the likelihood of success of the clinical assets of the underlying company in successfully completing clinical trials. An update to a clinical trial that shows some positive results in safety and especially efficacy, can increase the chance of success for that trial, which increases the value of the asset and the underlying company. The converse is true as well, for disappointing results.
Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and appro
... keep reading on reddit ➡
/r/news
https://www.nytimes.com/2021/06/11/us/west-point-high-school-valedictorian.html?smtyp=cur&smid=fb-nytimes&fbclid=IwAR3kvN4a2taoNIe8xIVHfeKzPhEwGXLo23wTqcfkOS2O1B3XLpYO9guKP3o
Consensus thinking is plaguing hedge funds right now - I used my understanding to buy $HZNP when $HZNP was a consensus short into December Symphony data readout. I also know many people here are considering a career in biotech investment / hedge fund - please read below to get a view on what's going on in hedge fund and how that culture essentially culminated in some crazy melt-up in $GME and other biotech names. $MRNA and $CRSP have been consensus HF shorts for a long time and this should explain why. What do you think are consensus HF short biotechs right now?
/r/news
https://www.nytimes.com/2021/04/15/us/politics/mike-pence-pacemaker-surgery.html?smid=url-share
